Compremium is developing new ways to diagnose venous, intracranial and tissue pressure conditions. [Photo courtesy of Compremium]
“This partnership is a pivotal step in advancing pediatric-specific technologies to address critical gaps in care,” Children’s National VP and Chief Innovation Officer Kolaleh Eskandanian said in a news release. “Compremium’s noninvasive, real-time pressure monitoring technology not only has the potential to transform pediatric care, but also demonstrates how prioritizing pediatric innovation can pave the way for broader adoption and scalability to adult populations.”
Switzerland-based Compremium is developing new ways to diagnose venous, intracranial and tissue pressure conditions.
Children’s National characterized the agreement as a first-of-its-kind strategic collaboration where Children’s National will “serve as the Pediatric Innovation Hub for Compremium, leading clinical studies, research projects, and commercialization efforts focused on non-invasive pressure monitoring and other breakthrough technologies.”
“This initiative allows us to accelerate and expand the clinical adoption of our solution, particularly for a vulnerable patient population,” Compremium CEO Vincent Baumann said.
The partnership will initially focus on congenital heart disease (CHD) patients, for which pediatric cardiologists require frequent, noninvasive monitoring of central venous pressure (CVP).
“Noninvasive CVP monitoring for the pediatric population is the holy grail of cardiac care, a long-awaited advancement that has the potential to revolutionize care,” Children’s National Cardiac Surgery Division Chief Dr. Yves d’Udekem said. “Pediatric cardiac surgeons worldwide are eager for this breakthrough solution, which could transform how we monitor and treat cardiovascular patients. It’s exciting to see this innovation, and we are thrilled that Children’s National is leading the way in bringing it to children everywhere.”
CVP measures blood volume returning to the heart and overall circulatory function, and Children’s National said improved CVP data could provide new cardiovascular insights, better interventions and fewer long-term complications such as developmental delays and learning difficulties, which affect approximately 33% of CHD patients in the U.S.
“By integrating Compremium’s cutting-edge technology with AI-driven advancements, we aim to enhance accuracy, enable real-time data analysis, and provide predictive insights — critical capabilities for improving pediatric care,” Eskandanian said. “Our pediatric providers are eager for innovative, child-friendly monitoring solutions that reduce the need for invasive procedures, and this collaboration is dedicated to making that a reality.”
Children’s National Hospital’s commercialization arm, Children’s National Innovation Ventures, led the collaboration agreement. Innovation Ventures leads two federally-funded accelerator programs and describes its mission as “advancing pediatric-driven technologies, building strategic industry alliances, facilitating funding to de-risk and validate innovations, and managing intellectual property and licensing to drive commercialization — all by supporting both internal and external innovation to accelerate pediatric health solutions.”
